Co-expression and predictive value of HER family members for the response to therapy with cetuximab in patients with metastatic colorectal cancer.

被引：0
|
作者：
Khelwatty, Said A. [1 ]
Puvanenthiran, Soozana [1 ]
Essapen, Sharadah [2 ]
Bagwan, Izhar [2 ]
Seddon, Alan M. [1 ]
Modjtahedi, Helmout [1 ]
机构：
[1] Kingston Univ London, Kingston Upon Thames, Surrey, England
[2] Royal Surrey Cty Hosp, Guildford, Surrey, England
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
350
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Angiogenesis modifications are predictive of response and outcome advanced colorectal cancer patients during therapy with cetuximab plus irinotecan
    Vincenzi, Bruno
    Santini, Daniele
    Russo, Antonio
    Dicuonzo, Giordano
    Gavasci, Michele
    Battistoni, Fabrizio
    Rocci, Laura
    Gebbia, Nicola
    Tonini, Giuseppe
    ANNALS OF ONCOLOGY, 2006, 17 : 258 - 258
  • [42] Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
    J B Baker
    D Dutta
    D Watson
    T Maddala
    B M Munneke
    S Shak
    E K Rowinsky
    L-A Xu
    C T Harbison
    E A Clark
    D J Mauro
    S Khambata-Ford
    British Journal of Cancer, 2011, 104 : 488 - 495
  • [43] A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: Predictive value of early specific toxicities
    Gamucci, Teresa
    Nelli, Fabrizio
    Cianci, Giovanni
    Grassi, Giulia
    Moscetti, Luca
    Sperduti, Isabella
    Zeuli, Massimo
    Cortesi, Enrico
    D'Auria, Giuliana
    Pollera, Camillo Francesco
    CLINICAL COLORECTAL CANCER, 2008, 7 (04) : 273 - 279
  • [44] Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients
    Cao, Guo-dong
    Chen, Ke
    Chen, Bo
    Xiong, Mao-ming
    BMC CANCER, 2017, 17
  • [45] Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients
    Guo-dong Cao
    Ke Chen
    Bo Chen
    Mao-ming Xiong
    BMC Cancer, 17
  • [46] Identification of a molecular signature of radiographic response to cetuximab in patients (pts) with advanced colorectal cancer.
    Garrett, C
    Takimoto, C
    Wojtowicz, M
    Burris, H
    Hidalgo, M
    Tan, B
    Krishnamurthi, S
    Basik, M
    Baselga, J
    Mauro, D
    Lee, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 277S - 277S
  • [47] Co-expression of HER3 in HER2-positive metastatic breast cancer patients is an independent predictor of impaired prognosis
    Berghoff, A. S.
    Bago-Horvath, Z.
    Preusser, M.
    Steger, G. G.
    Rudas, M.
    Birner, P.
    Zielinski, C. C.
    Bartsch, R.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S421 - S421
  • [48] Visceral fat as a predictive marker of response to bevacizumab -based treatment in metastatic colorectal cancer.
    Miyamoto, Yuji
    Sakamoto, Yasuo
    Watanabe, Masayuki
    Baba, Hideo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [49] Predictive value of D-dimer and LDH levels in response to chemotherapy in metastatic colorectal cancer patients
    Er, O.
    Inanc, M.
    Ozkan, M.
    Dogu, G. G.
    Dikilitas, M.
    Ozturk, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [50] Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study
    Ulivi, Paola
    Capelli, Laura
    Valgiusti, Martina
    Zoli, Wainer
    Scarpi, Emanuela
    Chiadini, Elisa
    Rosetti, Paola
    Bravaccini, Sara
    Calistri, Daniele
    Saragoni, Luca
    Gardini, Andrea Casadei
    Ragazzini, Angela
    Frassineti, Giovanni Luca
    Amadori, Dino
    Passardi, Alessandro
    JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10
12345